

# AN INTRODUCTION TO OTSUKA'S GLOBAL TB PROGRAM

## HISTORY OF NEW DRUG DISCOVERY

- Otsuka's drug discovery research began in 1971 with only 14 scientists who had the idea of addressing the world's unmet medical needs by investing in therapeutic areas that were underserved by other pharmaceutical companies.
- The corporate philosophy, "Otsuka: People creating new products for better health worldwide," embodies the company's dedication to creating unique and innovative products; improving health and well-being; and contributing to the everyday lives of patients.

## OTSUKA'S GLOBAL TB PROGRAM

- Otsuka has been involved in efforts to find new tuberculosis (TB) drugs for over 30 years. The company's global TB franchise includes new drugs, diagnostic tools, pediatric innovations and public health programs that provide a comprehensive approach to fighting back against TB.
- Otsuka is the largest private funder of TB drug development in the world.<sup>1</sup>
- In 2002, in-house scientists discovered a novel nitroimidazole compound, which is currently under Phase III testing for the treatment of multidrug-resistant TB (MDR-TB).
- Otsuka initiated the largest MDR-TB clinical trial ever conducted which includes the development of site infrastructure in countries affected by the disease.
- The goal of these efforts is to improve MDR-TB treatment regimens with responsible access to new compounds.
- Otsuka has chosen to invest in MDR-TB research because of the urgent unmet medical need in Asia and around the world:
  - Increasing rates of resistance to first line anti-TB treatments
  - 450,000 new cases of MDR-TB and 170,000 deaths per year<sup>2</sup>
  - Long treatment duration (18-24 months)
  - Poor treatment of TB can lead to extensively drug-resistant TB (XDR-TB)

## COMMITMENT TO FIGHTING TB IN CHILDREN


- Otsuka is also working towards an innovative MDR-TB treatment for children, which is a neglected population of an already neglected disease.
- Treating TB in children is challenging given difficulty in diagnosis, under-reporting of cases, and lack of child-friendly formulations.
- The company is developing the first novel children's formulation for MDR-TB and a Pediatric Investigation Plan (PIP) is already underway.

## PUBLIC HEALTH & CASE MANAGEMENT PROGRAMS

- Otsuka is also committed to developing public health and case management models that aim to reduce the spread of drug resistance, improve rational use of new TB drugs and prevent—not just treat—TB.
- Currently, the company is exploring case management models in Asia and Europe with the aim of improving TB care and control.
- Collaboration with partners, including international organizations, public health authorities, advocacy groups, and local NGOs, among others, is crucial to the success of these programs.

## GLOBAL TB BURDEN

- In 2012, 8.6 million people became sick, and nearly 1.3 million people died from TB, including 320,000 deaths among HIV-positive people.<sup>2</sup>
- In 2012, more than half of the estimated cases of MDR-TB were found in three countries:
  - India with 64,000 cases
  - China with 59,000 cases
  - The Russian Federation with 46,000 cases
- MDR-TB is nearly twice as prevalent in those infected with both TB and HIV/AIDS than in those with TB alone.



### FOR MORE INFORMATION, PLEASE CONTACT:

Marc Destito, Otsuka SA, Communications Director

Direct : +41 22 560 7964 Mobile : +41 78 881 0322

### REFERENCES

<sup>1</sup> Treatment Action Group (TAG) 2013 Report on Tuberculosis Research Funding Trends, 2005-2012

<http://www.treatmentactiongroup.org/tbrd2013>

<sup>2</sup> World Health Organization (WHO) Global Tuberculosis report 2013

[http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf)